Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

Also called NCT04952610

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04952610
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04952610. Allocation not applicable; no masking; primary purpose treatment. Start 2021-12-13 (actual); primary completion 2026-04-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Condition
Paroxysmal Supraventricular Tachycardia
Intervention (Drug)
Etripamil NS 70 mg
Intervention (Device)
Aptar Pharma Nasal Spray Bidose System
Lead sponsor
Milestone Pharmaceuticals Inc. (class: other)

Record details

Record id
cardio:ct-nct04952610
Content hash
03c17beb086819d19917e6b7e4a7943df613d52a95b1355f1f58ce3814372402